ACRS
Aclaris Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$460.13M
P/E Ratio
—
EPS
$-0.53
Beta
0.68
52W High
$4.89
52W Low
$1.05
50-Day MA
$3.50
200-Day MA
$2.52
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
-0.13
About Aclaris Therapeutics Inc
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a line of novel small molecule therapeutics to address the needs of patients with immuno-inflammatory diseases. The company is headquartered in Wayne, Pennsylvania.
Fundamentals
| Revenue (TTM) | $7.83M |
| Gross Profit (TTM) | $-52.10M |
| EBITDA | $-74.03M |
| Operating Margin | -1725.00% |
| Return on Equity | -50.20% |
| Return on Assets | -24.30% |
| Revenue/Share (TTM) | $0.06 |
| Book Value | $0.85 |
| Price-to-Book | 4.92 |
| Price-to-Sales (TTM) | 58.80 |
| EV/Revenue | 53.23 |
| EV/EBITDA | 0.28 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -85.90% |
| Shares Outstanding | $121.09M |
| Float | $89.69M |
| % Insiders | 2.57% |
| % Institutions | 77.66% |
Analyst Ratings
Consensus ($8.29 target)
1
Strong Buy6
Buy1
HoldData last updated: 4/7/2026